Rational Pharmacotherapy in Cardiology

Advanced search

Adverse Reactions of the Cardiovascular System when Taking Nonsteroidal Anti-inflammatory Drugs and Ways to Reduce Them

Full Text:


The most important issue of modern pharmacotherapy is not only efficacy, but also the safety of medicines. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the main methods of treating acute and chronic pain in a wide range of diseases and pathological conditions. However, the prescription of this group of drugs requires consideration of the potential risks of complications, including from the side of the cardiovascular system. The purpose of the review was to assess the adverse reactions of the cardiovascular system when taking NSAIDs and approaches to their reduction. The article presents data on the mutual potential impact of cardiovascular diseases and musculoskeletal system, presents the results of large-scale studies of Russian and foreign authors and meta-analyzes of the NSAIDs effect on blood pressure profile, development of myocardial infarction, stroke and heart failure. The possible pathogenetic mechanisms of the side effects of NSAIDs are reviewed; the complexity of managing comorbid patients is demonstrated; it is shown that symptomatic treatment of pain and inflammatory syndrome should be carried out considering a personalized approach to the patient and rational choice of drugs.

Before the NSAIDs prescription, it is necessary to consider all cardiovascular risk factors with the determination of the total risk of cardiovascular complications. In patients with a very high cardiovascular risk, the use of any NSAIDs should be avoided; with high and moderate risk, the use of NSAIDs with the most favorable cardiovascular safety profile is possible. If the patient belongs to the category of low total coronary risk, the doctor can choose any NSAIDs. 

About the Authors

N. V. Pyrikova
Altai State Medical University
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases, 

Lenina prosp. 40, Barnaul, 656038

O. N. Antropova
Altai State Medical University
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases,

Lenina prosp. 40, Barnaul, 656038

I. V. Osipova
Altai State Medical University
Russian Federation

MD, PhD, Professor, Head of Chair of Faculty Therapy and Occupational Diseases,

Lenina prosp. 40, Barnaul, 656038


1. Oganov R.G., Simanenkov V.I. Bakulin I.G. Clinical recommendations “Comorbid pathology in clinical practice”. Cardiovascular Therapy and Prevention. 2019;18(1):5-66 (In Russ.) DOI:10.15829/1728-8800-2019-1-5-66.

2. Barbour К.Е., Helmick С.G., Boring М., Brady Т.J. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR. 2017;66:9. DOI:10.15585/mmwr.mm6609e1.

3. Dougados M., Soubrier M., Antunez A., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8. DOI:10.1136/annrheumdis-2013-204223.

4. Karateev A.E., Popkova T.V., Novikova D.S. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the cis population: preliminary data of the CORONA-2 epidemiological survey. Rheumatology Science and Practice. 2014;52(6):600-6 (In Russ.) DOI:10.14412/1995-4484-2014-600-606.

5. Sellam J., Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80(6):568-73. DOI:10.15789/1563-0625-2016-4-317-330.

6. Karateev A.E., Nasonov E.L., Jahno N.N. Clinical recommendations “Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology. 2015;(1):4-23 (In Russ.) DOI:10.14412/1996-7012-2015-1-4-23.

7. Scarpignato C., Lanas A., Blandizzi C., et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis - an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55. DOI:10.1186/s12916-015-0285-8.

8. Zhuravleva M.V., Kukes V.G., Prokof'ev A.B. Rational use of NSAIDs - the balance of efficacy and safety (literature review). International Journal of Applied and Basic Research. 2016;6:687-96 (In Russ.)

9. Mitchell J.A., Kirkby N.S. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019;176(8):1038-50. DOI:10.1111/bph.14167.

10. Kirkby N.S., Chanb M.V., Zaissdet A.K., et al. Systematic study of constitutive cyclooxygenase-2 expression: role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci USA. 2016;113(2):434-9. DOI:10.1073/pnas.1517642113.

11. Atchison J.W., Herndon C.M., Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013;19(9 Suppl A):S3-19.

12. Asghar W., Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23:1-16. DOI:10.1007/s10787-014-0225-9.

13. Aghazadeh-Habashi A., Asghar W., Jamali F. Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. J Pharm Sci. 2018;107(2):756-63. DOI:10.1016/j.xphs.2017.09.020.

14. Asghar W., Aghazadeh-Habashi A., Jamali F. Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis. Inflammopharmacology 2017. DOI:10.1007/s10787-017-0344-1.

15. Nissen S.E., Yeomans N.D., Solomon D.H., et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-29. DOI:10.1056/NEJMoa1611593.

16. Ruschitzka F., Borer J.S., Krum H., et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282-92. DOI:10.1093/eurheartj/ehx508.

17. Lovell A.R., Ernst M.E. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017;19(5):39. DOI:10.1007/s11906-017-0736-z.

18. Karateev A.E. Destabilization of arterial hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: significance of the problem. Modern Rheumatology. 2018;12(2):64-72 (In Russ.) DOI:10.14412/1996-7012-2018-2-64-72.

19. Karateev A.E., Lila A.M., Churjukanov M.V. Evaluation of the effectiveness of the algorithm for the appointment of nonsteroidal anti-inflammatory drugs (NSAIDs), based on the analysis of risk factors for drug complications, in actual clinical practice. Results of the All-Russian project “PRINCIPLE” (Application of Recommendations on the Use of NSAIDs: Targeted Change of Practice). Scientific and Practical Rheumatology. 2017;55(5):485-92 (In Russ.) DOI:10.14412/1995-4484-2017-485-492.

20. Bhala N., Emberson J., Merhi A. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013;382(9894):769-79. DOI:10.1016/S0140-6736(13)60900-9.

21. Varas-Lorenzo C., Riera-Guardia N., Calingaert B., et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559-70. DOI:10.1002/pds.

22. Gunter B.R., Butler K.A., Wallace R., et al. Non-steroidal anti-inflammatory druginduced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42(1):27-38. DOI:10.1111/jcpt.12484.

23. Bally M., Dendukuri N., Rich B., et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 20179;357:j1909. DOI:10.1136/bmj.j1909.

24. Dong Y.H., Chang C.H., Wu L.C., et al. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. Br J Clin Pharmacol. 2018;84(5):1045-56. DOI:10.1111/bcp.13537.

25. Harirforoosh S., Asghar W., Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-7. DOI:10.18433/J3VW2F.

26. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343:1520-8. DOI:10.1056/NEJM200011233432103.

27. Varas-Lorenzo C., Riera-Guardia N., Calingaert B., et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011;20(12):1225-36. DOI:10.1007/s11739-015-1288-3.

28. Islam M.M., Poly T.N., Walther B.A., et al. Risk of Hemorrhagic Stroke in Patients Exposed to Nonsteroidal Anti-Inflammatory Drugs: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2018;51(3-4):166-76. DOI:10.1159/000490741.

29. Rotunno R., Oppo I., Saetta G., et al. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis. 2018;88(2):950. DOI:10.4081/monaldi.2018.950.

30. Arfè A., Scotti L., Varas-Lorenzo C., et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857. DOI:10.1136/bmj.i4857.

31. Huang S.P., Wen Y.C., Huang S.T., et al. Nonsteroidal Anti-Inflammatory Drugs and Risk of First Hospitalization for Heart Failure in Patients with No History of Heart Failure: A Population-Based CaseCrossover Study. Drug Saf. 2019;42(1):67-75. DOI:10.1007/s40264-018-0720-9.

32. Daniell H.W. Gastroesophageal reflux disease stimulation of NSAID-associated atrial fibrillation. Arch Intern Med. 2011;171(7):704-5. DOI:10.1001/archinternmed.2011.107.

33. Ricci F., De Caterina R. Relations between FANS, PPI and atrial fibrillation. Recenti Prog Med. 2013;104(5):209-13. DOI:10.1701/1291.14278.

34. Linz D., Hohl M., Vollmar J., et al. Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. EP Europace. 2017;19(1):16-20. DOI:10.1093/europace/euw092.

35. Lanas A., Benito P., Alonso J., et al. Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG). Reumatol Clin. 2014;10(2):68-84. DOI:10.1016/j.reuma.2013.10.004.

36. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. DOI:10.1093/eurheartj/ehw106.

37. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7- 122. (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.

38. Ljungman C., Kahan T., Schiller L., et al. Non-steroidal anti-inflammatory drugs and blood pressure control in patients treated for hypertension: results from the Swedish primary care cardiovascular database. Blood Press. 2017;26(4):220-8. DOI:10.1080/08037051.2017.1290503.

39. Villa J., Cano A., Franco D., et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria. 2014;46(9):464-74. DOI:10.1016/j.aprim.2013.11.010.

40. Ikeda Y., Shimada K., Teramoto T., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510-20. DOI:10.1001/jama.2014.15690.

41. Hennekens C.H., Dalen J.E. Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs. Trends Cardiovasc Med. 2014;24(8):360-6. DOI:10.1016/j.tcm.2014.08.006.

42. Da Costa B.R., Reichenbach S., Keller N., et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387(10033):2093-105. DOI:10.1016/S0140-6736(16)30002-2.

For citation:

Pyrikova N.V., Antropova O.N., Osipova I.V. Adverse Reactions of the Cardiovascular System when Taking Nonsteroidal Anti-inflammatory Drugs and Ways to Reduce Them. Rational Pharmacotherapy in Cardiology. 2019;15(5):750-758. (In Russ.)

Views: 21

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)